You are here

Banks line up £1.4b financing for possible LGC sale

[LONDON] Bankers are working on debt financings totalling around £1.4b($S2.4 billion) equivalent to back a potential sale of UK forensic sciences group LGC as potential buyers get set to submit bids.

KKR acquired LGC from Bridgepoint in December 2015 and has put the company up for sale, with first round bids due on October 8 in an auction process.

Advent, Bain, Blackstone, Carlyle, Cinven, EQT and H&F are expected to submit bids for the company, which has also attracted the attention of trade buyers including medical device makers Thermo Fisher Scientific and Danaher, banking sources said.

All of the private equity firms and trade buyers either declined to comment or were not immeditaley available to comment.

Market voices on:

JP Morgan, HSBC and KKR Capital Markets are expected to provide a staple financing backing a possible sale that will be offered to all sponsors.

The staple financing is expected to comprise senior and junior leveraged loans denominated in euros and dollars. It will total around 7.5-7.75 times LGC's approximate £165m-£170m Ebitda, the sources said.

Other banks are also working on financing packages of similar levels to back private equity firms looking to bid.

At 7.5-7.75 times, the leverage levels are quite aggressive, but LGC is a strong performer that is well known to the leveraged loan market, banking sources said.

"LGC is awesome. Every bank will want a piece of it," a syndicate head said.

LGC last tapped the loan market in July 2019 when it raised an incremental €210m-equivalent leveraged loan to fund upcoming acquisitions. KKR was sole arranger of the loans, with Wilmington Trust acting as agent.